Source comparison
MK-677 History: Comparison Across Research Milestones
The evolution of MK-677 as a research compound can be mapped through key clinical and regulatory milestones. Understanding these phases clarifies why certain dosing protocols became standard and which applications gained traction in biological research. Discov
This comparison does not assign a generated winner or score.
- The evolution of MK-677 as a research compound can be mapped through key clinical and regulatory milestones. Understanding these phases clarifies why certain dosing protocols became standard and which applications gained traction in biological research.
- Discovery & Synthesis
- 1993–1995
- Reverse Pharmacology identifies ibutamoren as first oral ghrelin receptor agonist
- Non-peptide structure with oral bioavailability confirmed; 24-hour half-life
- Enabled growth hormone research without injection protocols
- Solved the peptide bioavailability problem that limited prior GH secretagogues
- Early Clinical Trials
- 1997–1999
- Phase I/II trials demonstrate dose-dependent GH and IGF-1 elevation in healthy adults
- 25mg daily increased IGF-1 by 39–97%; mild edema and glucose elevation noted
- Established dosing range and safety markers for subsequent trials
- Proved concept but flagged metabolic trade-offs
- Merck Acquisition
- 1999
- Merck purchases Reverse Pharmacology; begins large-scale elderly population trials
- Two-year trial shows 1.1 kg lean mass increase but no bone density improvement
- Shifted focus from niche research to potential sarcopenia/frailty indication
- Brought funding but narrowed compound focus to geriatric applications
- Extended Trials
- 2001–2008
- Multi-year studies on bone density, sleep, and metabolic effects in aging populations
- REM sleep improved 50%; fasting glucose increased 6–8 mg/dL; no cognitive benefit
- Clarified secondary effects and limitations; metabolic concerns emerged
- Defined the trade-offs that prevented FDA approval
- Regulatory Decision
- 2008–2010
- Merck discontinues development; does not file for FDA approval
- Compound remains available for research use but not as prescription medication
- Preserved research access while avoiding chronic-use liability
- Ensured MK-677 remained a research tool, not a pharmaceutical product
- Research Continuity
- 2010–Present
- Independent studies continue exploring growth hormone pathways, body composition, and metabolic regulation
- Ongoing citations in studies on ghrelin signaling, muscle protein synthesis, and aging biology
- Sustained relevance in biological research despite lack of FDA approval
- MK-677 history transitioned from drug candidate to established research compound
- This timeline shows that the MK-677 history is not linear. It's a case study in how a compound's value shifts depending on regulatory context and research objectives. The same pharmacological properties that made it unsuitable for chronic prescription use make it highly valuable for controlled studies on growth hormone physiology.